Merck & Company, Inc. Press Releases

MRK 
$53.84
*  
1.53
2.76%
Get MRK Alerts
*Delayed - data as of Aug. 31, 2015 15:44 ET  -  Find a broker to begin trading MRK now
Exchange: NYSE
Industry: Health Care
Community Rating:
View:    MRK After Hours
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks
Viewing
Filtered By
Ordered By

New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN® (ezetimibe and simvastatin) and the TECOS Cardiovascular Safety Trial of JANUVIA® (sitagliptin) Will Be Presented at the European Society of Cardiology Congress
8/20/2015 8:30:00 AM - Business Wire
▼-9.42 % Price Change since this news event. The Volume Ratio is 3.27.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Recalls TEMODAR® and Temozolomide Bottles with Cracked Caps Due to Failure to Meet Child–Resistant Closure Requirement
8/18/2015 1:17:00 PM - Business Wire
▼-9.77 % Price Change since this news event. The Volume Ratio is 1.74.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


FDA Accepts Supplemental Biologics License Application (sBLA) for KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, for First-Line Treatment of Advanced Melanoma, and Grants Priority Review
8/18/2015 8:00:00 AM - Business Wire
▼-9.92 % Price Change since this news event. The Volume Ratio is 1.06.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Celebrity Chef Leticia Moreinos Schwartz, Merck and the American Diabetes Association Challenge Hispanics with Type 2 Diabetes to Get to Their A1C Goal
8/14/2015 8:00:00 AM - PR Newswire
▼-8.71 % Price Change since this news event. The Volume Ratio is 1.67.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck and MD Anderson Cancer Center Announce Strategic Immuno-Oncology Research Collaboration in Solid Tumors
8/13/2015 8:00:00 AM - Business Wire
▼-7.97 % Price Change since this news event. The Volume Ratio is 2.61.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day






In Interim Results from Phase 3 Study, Merck’s Investigational Ebola Vaccine Efficacious; Study is Continuing
7/31/2015 8:10:00 AM - Business Wire
▼-8.75 % Price Change since this news event. The Volume Ratio is 0.76.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Celebrity Chef Leticia Moreinos Schwartz, Merck and the American Diabetes Association Challenge Hispanics with Type 2 Diabetes to Get to Their A1C Goal
7/30/2015 8:00:00 AM - PR Newswire
▼-7.93 % Price Change since this news event. The Volume Ratio is 0.64.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Pamela J. Craig and Dr. Paul B. Rothman Elected to Merck Board of Directors
7/28/2015 4:15:00 PM - Business Wire
▼-6.40 % Price Change since this news event. The Volume Ratio is 1.63.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day




Merck Announces Second-Quarter 2015 Financial Results
7/28/2015 7:00:00 AM - Business Wire
▼-5.56 % Price Change since this news event. The Volume Ratio is 2.45.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Enhances Immuno-Oncology Portfolio with Acquisition of cCAM Biotherapeutics
7/28/2015 6:45:00 AM - Business Wire
▼-5.56 % Price Change since this news event. The Volume Ratio is 2.45.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Grazoprevir/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Genotypes 1, 4 and 6 Infection
7/28/2015 6:30:00 AM - Business Wire
▼-5.56 % Price Change since this news event. The Volume Ratio is 2.45.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Receives Positive CHMP Opinion for Investigational Antibiotic ZERBAXA™ (Ceftolozane and Tazobactam)
7/27/2015 8:30:00 AM - Business Wire
▼-5.96 % Price Change since this news event. The Volume Ratio is 3.11.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Announces European Medicines Agency Acceptance of Marketing Authorization Application for Grazoprevir/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Infection
7/23/2015 11:02:00 AM - Business Wire
▼-7.38 % Price Change since this news event. The Volume Ratio is 1.41.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


MSD Announces European Medicines Agency Acceptance of Marketing Authorisation Application for Grazoprevir/Elbasvir, an Investigational Therapy for Treatment of Chronic Hepatitis C Infection
7/23/2015 11:02:00 AM - Business Wire
▼-7.41 % Price Change since this news event. The Volume Ratio is 1.42.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Announces Fourth-Quarter 2015 Dividend
7/22/2015 1:28:00 PM - Business Wire
▼-7.49 % Price Change since this news event. The Volume Ratio is 3.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


European Commission Approves MSD’s Anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab), for Both First-line and Previously-treated Patients with Advanced Melanoma
7/22/2015 7:00:00 AM - Business Wire
▼-7.97 % Price Change since this news event. The Volume Ratio is 1.9.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


European Commission Approves Merck’s Anti-PD-1 Therapy, KEYTRUDA® (pembrolizumab), for Both First-line and Previously-treated Patients with Advanced Melanoma
7/22/2015 7:00:00 AM - Business Wire
▼-7.97 % Price Change since this news event. The Volume Ratio is 1.9.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Merck Marks 30-Year Milestone in Commitment to Innovation and Care in HIV/AIDS
7/21/2015 8:00:00 AM - Business Wire
▼-9.15 % Price Change since this news event. The Volume Ratio is 1.49.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day


Award-Winning Actress S. Epatha Merkerson, Merck and the American Diabetes Association Challenge African Americans with Type 2 Diabetes to Get to Their A1C Goal
7/15/2015 8:00:00 AM - PR Newswire
▼-7.17 % Price Change since this news event. The Volume Ratio is 0.79.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day






Merck Announces Phase 3 Study of Single-Dose EMEND® (fosaprepitant dimeglumine) for Injection Regimen Met Primary Endpoint in Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy
6/29/2015 8:30:00 AM - Business Wire
▼-7.06 % Price Change since this news event. The Volume Ratio is 1.45.This reflects the trading volume for the event day.  Source: NewsQuantified.com
Volume ratio on event day